Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
24 Maio 2023 - 5:01PM
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ:
GRCL), a global clinical-stage biopharmaceutical company dedicated
to developing highly efficacious and affordable cell therapies for
the treatment of cancer and autoimmune diseases, today announced
that the management team will participate in the Jefferies
Healthcare Conference on June 8, 2023, in New York, NY.
The Gracell team is scheduled to present on June 8th at 8:00 am
ET and will host investor meetings at the conference.
A webcast of the presentation will be available on the News
and Events section of the Company's website. A replay of the
webcast will be available for 90 days following the event. For more
information, please visit ir.gracellbio.com.
About Gracell Gracell Biotechnologies
Inc. ("Gracell") is a global clinical-stage biopharmaceutical
company dedicated to discovering and developing breakthrough cell
and gene therapies. Leveraging its pioneering FasTCAR and TruUCAR
technology platforms and SMART CART™ technology
module, Gracell is developing a rich clinical-stage pipeline
of multiple autologous and allogeneic product candidates with the
potential to overcome major industry challenges that persist with
conventional CAR-T therapies, including lengthy manufacturing time,
suboptimal cell quality, high therapy cost and lack of effective
CAR-T therapies for solid tumors. For more information on Gracell,
please visit www.gracellbio.com. Follow @GracellBio on
LinkedIn.
Media contacts
Marvin Tang
marvin.tang@gracellbio.com
Jessica Laub
jessica.laub@westwicke.com
Investor contacts
Gracie Tong
gracie.tong@gracellbio.com
Stephanie Carrington
stephanie.carrington@westwicke.com
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024